Pfizer Prevnar vaccine wins approval for ages 6-17

Sat Jan 26, 2013 3:41am IST

Related Topics

Stocks

   

(Reuters) - Pfizer Inc on Friday said U.S. regulators had approved wider use of its Prevnar 13 vaccine to prevent infections with pneumococcal bacteria, for children and adolescents aged 6 years to 17 years.

The product was already approved in the United States to prevent infections among children aged 6 weeks through 5 years. It is also approved for adults aged 50 and older.

The vaccine protects against infection with 13 strains of the Streptococcus pneumoniae bacterium. The bacterium can cause pneumonia, ear infections and other problems.

Prevnar 13 has annual sales of about $3.5 billion, making it Pfizer's third-biggest brand. It was approved in 2010, and has largely displaced an older vaccine called Prevnar, which protected against only 7 prevalent strains of the bacterium.

(Reporting by Ransdell Pierson; Editing by David Gregorio and Dan Grebler)

FILED UNDER:

Reuters Showcase

Sahara Saga

Sahara Saga

Some staff say Sahara has not paid salaries for months   Read 

Jihadi John

Jihadi John

British PM Cameron vows to hunt down 'Jihadi John'.  Full Article 

Economic Survey

Economic Survey

India in "sweet spot" of lower deficits, more growth - Economic Survey.  Full Article 

Movie Review

Movie Review

"Dum Laga Ke Haisha" is rooted in reality, writes Shilpa Jamkhandikar.  Read | Ab Tak Chhappan 

Nimoy Dies

Nimoy Dies

Leonard Nimoy, Star Trek's 'Mr. Spock,' dies at 83.  Full Article 

Gown Returned

Gown Returned

Lupita Nyong'o's $150,000 Oscar gown returned by thief via TMZ.  Full Article 

NZ vs Australia

NZ vs Australia

Boult destroys powerful Australia batting lineup.  Full Article 

World Cup 2015

World Cup 2015

Full coverage of cricket world cup in Australia and New Zealand.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage